EXPLORE!

Dupilumab gets FDA approval as add-on maintenance therapy for moderate-to-severe asthma

  1025 Views

eMediNexus    24 October 2018

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Sanofi/Regeneron) as “add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma”. Dupilumab will be available as an injectable solution in prefilled syringes with 200-mg and 300-mg doses administered every other week.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.